Investor Relations

Press Releases

Date Title and Summary View
Jun 27, 2017
PRINCETON, N.J., June 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration (FDA) the NDA for its lead product candidate, Twirla ® , an investigational low-dose combined
May 08, 2017

Cash Expected to Fund Operations into Q2 2018

May 06, 2017

Newly Reported Bleeding Profile Shows Reduction in Unscheduled Bleeding/Spotting Days

May 03, 2017
PRINCETON, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company today announced that data from its Phase 3 SECURE study will be presented at the interactive ePoster session during the 2017 Annual Clinical and Scientific Meeting of the American
Apr 27, 2017
PRINCETON, N.J., April 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company announced today that a presentation entitled " An Update on Hormonal Contraception and The Changing U.S. Population " will be presented by Co-Principal Investigator of the SECURE
Apr 11, 2017

Confirms Plans to Re-submit New Drug Application for Twirla® by the end of the Second Quarter of 2017

Mar 16, 2017
PRINCETON, N.J., March 16, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, announced a poster presentation of data from the SECURE Phase 3 clinical trial for its lead product candidate, Twirla ® , (ethinyl estradiol and levonorgestrel transdermal
Mar 08, 2017

Current Business Plan Expected to Extend Cash Position and Fund Operations into Q2 2018

Mar 01, 2017

Presentation Scheduled on Monday, March 13, 2017 at 4:30 PM Pacific Time

Feb 14, 2017

Presentation Scheduled on February 23, 2017 at 10:00 AM ET